ストックスクリーナーアプリを入手
1.98
7.04%
-0.15
アフターアワーズ：
1.96
-0.02
-1.01%
前日終値:
$2.13
開ける：
$2.14
24時間の取引高:
144.14K
Relative Volume:
0.81
時価総額：
$52.85M
収益：
$48.20M
当期純損益:
$-35.05M
株価収益率:
-1.2633
EPS:
-1.5673
ネットキャッシュフロー:
$-13.02M
1週間 パフォーマンス:
-3.41%
1か月 パフォーマンス:
-7.91%
6か月 パフォーマンス:
+27.33%
1年 パフォーマンス:
-23.85%
1日の値動き範囲:
$1.931
$2.14
1週間の範囲:
$1.931
$2.35
52週間の値動き範囲:
$1.06
$5.22
Celularity Inc Stock (CELU) Company Profile
CELU を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CELU
Celularity Inc
|
1.98 | 56.85M | 48.20M | -35.05M | -13.02M | -1.5673 |
|
VRTX
Vertex Pharmaceuticals Inc
|
416.81 | 104.76B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
481.67 | 63.06B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
578.05 | 60.32B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
843.66 | 51.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
165.76 | 34.49B | 398.11M | -1.03B | -868.57M | -5.7032 |
Celularity Inc Stock (CELU) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2023-01-30 | ダウングレード | Morgan Stanley | Equal-Weight → Underweight |
| 2022-12-22 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2022-06-22 | 開始されました | H.C. Wainwright | Buy |
| 2022-04-06 | ダウングレード | Truist | Buy → Hold |
| 2022-01-28 | 開始されました | Oppenheimer | Outperform |
| 2021-11-24 | 開始されました | Morgan Stanley | Equal-Weight |
すべてを表示
Celularity Inc (CELU) 最新ニュース
How sentiment analysis helps forecast Celularity Inc.Earnings Performance Report & Growth Focused Stock Reports - newser.com
Using Python tools to backtest Celularity Inc. Equity Warrant strategiesAnalyst Upgrade & Daily Profit Focused Stock Screening - newser.com
Candlestick signals on Celularity Inc. stock todayRate Cut & Low Risk Growth Stock Ideas - newser.com
How to recover losses in Celularity Inc. Equity Warrant stockWeekly Trade Analysis & Capital Efficiency Focused Ideas - newser.com
How Celularity Inc. stock performs during Fed tightening cyclesPortfolio Profit Report & Technical Entry and Exit Alerts - newser.com
Celularity Inc. Equity Warrant stock trendline breakdown2025 Geopolitical Influence & AI Based Buy/Sell Signal Reports - newser.com
Celularity Inc. Equity Warrant stock outlook for YEARQuarterly Portfolio Report & Low Risk Investment Opportunities - newser.com
What momentum shifts mean for Celularity Inc. Equity WarrantWeekly Volume Report & Technical Pattern Recognition Alerts - newser.com
Is Celularity Inc. Equity Warrant stock supported by strong cash flowsQuarterly Trade Review & Technical Pattern Based Buy Signals - newser.com
Published on: 2025-10-15 11:28:29 - newser.com
Multi asset correlation models including Celularity Inc. Equity WarrantDividend Hike & Real-Time Stock Entry Alerts - newser.com
Applying big data sentiment scoring on Celularity Inc. Equity Warrant2025 Biggest Moves & Short-Term Trading Opportunity Alerts - newser.com
Can Celularity Inc. Equity Warrant stock sustain market leadershipTrade Risk Assessment & Low Volatility Stock Suggestions - newser.com
Using data models to predict Celularity Inc. stock movementEntry Point & AI Forecasted Entry/Exit Points - newser.com
Is Celularity Inc. forming a bottoming baseBull Run & Real-Time Chart Breakout Alerts - newser.com
Celularity Announces Peer-Reviewed Publication of Phase 2 Clinical Trial Results Demonstrating the Safety and Efficacy of Human Placenta-Derived Cells for Diabetic Foot Ulcers Complicated by Peripheral Artery Disease - Investing News Network
Evaluating Celularity Inc. with trendline analysisShare Buyback & Scalable Portfolio Growth Ideas - newser.com
Is Celularity Inc. Equity Warrant stock cheap at current valuationWeekly Profit Analysis & Community Supported Trade Ideas - newser.com
Celularity’s diabetic foot ulcer therapy shows promise in clinical trial By Investing.com - Investing.com Canada
Published on: 2025-10-14 13:50:00 - newser.com
Celularity’s diabetic foot ulcer therapy shows promise in clinical trial - Investing.com
Celularity Inc. Announces Positive Phase 2 Results for PDA-002 in Treating Diabetic Foot Ulcers Complicated by Peripheral Artery Disease - Quiver Quantitative
Celularity Announces Peer-Reviewed Publication of Phase 2 Clinical Trial Results Demonstrating the Safety and Efficacy of Human Placenta-Derived Cells (PDA-002) for Diabetic Foot Ulcers Complicated by Peripheral Artery Disease - Stock Titan
Is Celularity Inc. stock cheap at current valuationJuly 2025 Closing Moves & Weekly High Return Forecasts - newser.com
How to track smart money flows in Celularity Inc. Equity Warrant2025 Big Picture & Verified Entry Point Signals - newser.com
Celularity Inc. Equity Warrant recovery potential after sell off2025 Earnings Surprises & Community Consensus Trade Alerts - newser.com
Published on: 2025-10-14 00:55:53 - newser.com
Analyzing Celularity Inc. with multi timeframe charts2025 Market Sentiment & Weekly High Return Opportunities - newser.com
Can Celularity Inc. stock hit analyst price targetsJuly 2025 PreEarnings & Real-Time Price Movement Reports - newser.com
Celularity Inc (CELU) 財務データ
収益
当期純利益
現金流量
EPS
1.84%
0.50%
大文字化:
|
ボリューム (24 時間):